Invivyd Announces Initial Data From Ongoing Phase 1 Clinical Trial Of VYD222
Portfolio Pulse from Bill Haddad
Invivyd announces initial data from its ongoing Phase 1 clinical trial of VYD222, showing strong neutralization activity against the Omicron XBB.1.5 variant. The drug has been well-tolerated with no serious adverse events reported, supporting a rapid transition to a pivotal clinical trial.
June 22, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Invivyd's VYD222 demonstrates strong neutralization against the Omicron XBB.1.5 variant in Phase 1 trial, with no serious adverse events, supporting a rapid transition to a pivotal clinical trial.
The positive initial data from the Phase 1 trial of VYD222 indicates that the drug is effective against the Omicron XBB.1.5 variant and has been well-tolerated. This supports a rapid transition to a pivotal clinical trial, which could lead to potential regulatory approval and commercialization. As a result, this news is likely to have a positive short-term impact on Invivyd's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100